Plazomicin Is Active Against Metallo-β-Lactamase-Producing Enterobacteriaceae
| Autor: | Kevin M. Krause, Tiffany R. Keepers, Alisa W Serio |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Klebsiella pneumoniae medicine.drug_class metallo-β-lactamase 030106 microbiology Antibiotics Plazomicin medicine.disease_cause Microbiology 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Medicine 030212 general & internal medicine Escherichia coli biology business.industry Aminoglycoside biology.organism_classification Proteus mirabilis Enterobacteriaceae Infectious Diseases Oncology chemistry aminoglycoside Brief Reports plazomicin business Enterobacter cloacae |
| Zdroj: | Open Forum Infectious Diseases |
| ISSN: | 2328-8957 |
| Popis: | Plazomicin is an aminoglycoside that was approved in June 2018 by the US Food and Drug Administration for the treatment of complicated urinary tract infections, including pyelonephritis, due to Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, and Proteus mirabilis. Plazomicin was engineered to overcome the most common aminoglycoside resistance mechanism, inactivation by aminoglycoside-modifying enzymes, but is not active against the less common 16S ribosomal RNA methyltransferases (16S-RMTase), which confer target site modification. As an aminoglycoside, plazomicin maintains activity against Enterobacteriaceae that express resistance mechanisms to other antibiotic classes, including metallo-β-lactamases. Therefore, in the absence of a 16S-RMTase, plazomicin is active against metallo-β-lactamase-producing Enterobacteriaceae. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|